JP2023502780A5 - - Google Patents
Info
- Publication number
- JP2023502780A5 JP2023502780A5 JP2022530237A JP2022530237A JP2023502780A5 JP 2023502780 A5 JP2023502780 A5 JP 2023502780A5 JP 2022530237 A JP2022530237 A JP 2022530237A JP 2022530237 A JP2022530237 A JP 2022530237A JP 2023502780 A5 JP2023502780 A5 JP 2023502780A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025133444A JP2025159098A (ja) | 2019-11-25 | 2025-08-08 | 腫瘍浸潤リンパ球の活性化及び増殖方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962940035P | 2019-11-25 | 2019-11-25 | |
| US62/940,035 | 2019-11-25 | ||
| US202063081539P | 2020-09-22 | 2020-09-22 | |
| US63/081,539 | 2020-09-22 | ||
| PCT/US2020/062094 WO2021108455A1 (en) | 2019-11-25 | 2020-11-24 | Methods for activation and expansion of tumor infiltrating lymphocytes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025133444A Division JP2025159098A (ja) | 2019-11-25 | 2025-08-08 | 腫瘍浸潤リンパ球の活性化及び増殖方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023502780A JP2023502780A (ja) | 2023-01-25 |
| JPWO2021108455A5 JPWO2021108455A5 (https=) | 2023-12-01 |
| JP2023502780A5 true JP2023502780A5 (https=) | 2023-12-01 |
Family
ID=76128945
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022530237A Withdrawn JP2023502780A (ja) | 2019-11-25 | 2020-11-24 | 腫瘍浸潤リンパ球の活性化及び増殖方法 |
| JP2025133444A Pending JP2025159098A (ja) | 2019-11-25 | 2025-08-08 | 腫瘍浸潤リンパ球の活性化及び増殖方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025133444A Pending JP2025159098A (ja) | 2019-11-25 | 2025-08-08 | 腫瘍浸潤リンパ球の活性化及び増殖方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240376428A1 (https=) |
| EP (1) | EP4065233A4 (https=) |
| JP (2) | JP2023502780A (https=) |
| KR (1) | KR20220119038A (https=) |
| CN (1) | CN115003387A (https=) |
| AU (1) | AU2020392094A1 (https=) |
| CA (1) | CA3162272A1 (https=) |
| WO (1) | WO2021108455A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| US12365871B2 (en) | 2020-04-28 | 2025-07-22 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| WO2021252804A1 (en) | 2020-06-12 | 2021-12-16 | Nkarta, Inc. | Genetically modified natural killer cells for cd70-directed cancer immunotherapy |
| CN114901805B (zh) | 2020-11-19 | 2023-07-25 | 苏州沙砾生物科技有限公司 | 肿瘤浸润淋巴细胞的培养方法及其用途 |
| CN117616115A (zh) * | 2021-08-03 | 2024-02-27 | 苏州沙砾生物科技有限公司 | 一种修饰的肿瘤浸润淋巴细胞及其用途 |
| WO2023039410A1 (en) * | 2021-09-08 | 2023-03-16 | KSQ Therapeutics, Inc. | Lymphocyte potency assay |
| CN118414422A (zh) * | 2021-12-30 | 2024-07-30 | 苏州沙砾生物科技有限公司 | 一种修饰的肿瘤浸润淋巴细胞及其用途 |
| WO2023138598A1 (zh) * | 2022-01-19 | 2023-07-27 | 苏州沙砾生物科技有限公司 | 肿瘤浸润淋巴细胞在疾病治疗中的用途 |
| EP4471128A4 (en) * | 2022-01-29 | 2026-03-04 | Suzhou Grit Biotechnology Co Ltd | Modified tumor infiltrating lymphocyte and use thereof |
| CA3254363A1 (en) * | 2022-03-07 | 2023-09-14 | Nkarta, Inc. | Multiplex gene-edited cells for CD70-led cancer immunotherapy |
| CN117417894A (zh) * | 2023-09-15 | 2024-01-19 | 毕诺济(上海)生物技术有限公司 | 敲除Roquin-1和/或Regnase-1基因的肿瘤浸润淋巴细胞及其应用 |
| WO2025092690A1 (zh) * | 2023-10-30 | 2025-05-08 | 苏州沙砾生物科技有限公司 | 一种修饰的细胞及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008522951A (ja) * | 2004-07-19 | 2008-07-03 | ベイラー・カレツジ・オブ・メデイシン | サイトカインシグナル伝達調節物質の調節および免疫療法のための応用 |
| WO2010098429A1 (ja) * | 2009-02-27 | 2010-09-02 | 国立大学法人大阪大学 | 免疫アジュバント組成物、及びその利用 |
| EP2711418B1 (en) * | 2012-09-25 | 2017-08-23 | Miltenyi Biotec GmbH | Method for polyclonal stimulation of T cells by flexible nanomatrices |
| WO2015188228A1 (en) * | 2014-06-10 | 2015-12-17 | Monash University | Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer |
| BR112017004270B1 (pt) * | 2014-09-04 | 2023-03-07 | Stemcell Technologies Inc | Método de ativação de células t ou células nk |
| CA3197849A1 (en) * | 2014-12-29 | 2016-07-07 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| SG11201708516YA (en) * | 2015-04-17 | 2017-11-29 | David Maxwell Barrett | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| WO2017087784A1 (en) * | 2015-11-18 | 2017-05-26 | Duke University | Tumor infiltrating lymphocytes for treatment of cancer |
| TWI788307B (zh) * | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| US11261428B2 (en) * | 2018-03-15 | 2022-03-01 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| US20200224161A1 (en) * | 2017-05-10 | 2020-07-16 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
| KR20200130826A (ko) * | 2018-03-15 | 2020-11-20 | 케이에스큐 세러퓨틱스 인코포레이티드 | 개선된 면역요법을 위한 유전자-조절 조성물 및 방법 |
| CN108753718A (zh) * | 2018-06-20 | 2018-11-06 | 淮安诺康生物科技有限公司 | 肿瘤浸润淋巴细胞til的体外扩增方法 |
-
2020
- 2020-11-24 KR KR1020227021333A patent/KR20220119038A/ko active Pending
- 2020-11-24 US US17/779,458 patent/US20240376428A1/en active Pending
- 2020-11-24 EP EP20892396.1A patent/EP4065233A4/en active Pending
- 2020-11-24 JP JP2022530237A patent/JP2023502780A/ja not_active Withdrawn
- 2020-11-24 WO PCT/US2020/062094 patent/WO2021108455A1/en not_active Ceased
- 2020-11-24 CN CN202080093941.8A patent/CN115003387A/zh active Pending
- 2020-11-24 AU AU2020392094A patent/AU2020392094A1/en active Pending
- 2020-11-24 CA CA3162272A patent/CA3162272A1/en active Pending
-
2025
- 2025-08-08 JP JP2025133444A patent/JP2025159098A/ja active Pending